Table 2.
Cp | RHS | hHSD1 % inh at 10 µM b | hHSD1 IC50 (µM) | HEK hHSD1 % inh at 10 µM c | HEK hHSD2 % inh at 10 µM c | HLM % Parent d |
---|---|---|---|---|---|---|
2 | 100 | 0.019 | 100 | 69 | 27 | |
4 | 100 | 0.546 | 77 | 84 | 85 | |
5 | 100 | 4.265 | ND | ND | ND | |
6 | 100 | 0.666 | 41 | 71 | 60 | |
7 | 49 | ND | ND | ND | ND | |
8 | 100 | 0.045 | 100 | 86 | 13 | |
9 | 100 | 0.056 | 100 | 87 | 44 | |
10 | 0 | ND | ND | ND | ND | |
11 | 23 | ND | ND | ND | ND | |
12 | 3 | ND | ND | ND | ND | |
13 | 0 | ND | ND | ND | ND | |
14 | 100 | 5.441 | ND | ND | ND | |
15 | 100 | 11.560 | ND | ND | ND | |
16 | 100 | 0.377 | 100 | 53 | 13 |
a See Experimental section for further details; b Percentage inhibition was determined relative to a no inhibitor control; c HEK293 cells stably transfected with the full-length gene coding for human either 11β-HSD1 or 11β-HSD2 were used; d Percentage of remaining compound after 30-min incubation period in HLM. ND, not determined.